<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Sci</journal-id><journal-id journal-id-type="iso-abbrev">Brain Sci</journal-id><journal-id journal-id-type="publisher-id">brainsci</journal-id><journal-title-group><journal-title>Brain Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3425</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6680509</article-id><article-id pub-id-type="doi">10.3390/brainsci9070172</article-id><article-id pub-id-type="publisher-id">brainsci-09-00172</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6723-7019</contrib-id><name><surname>Lombardo</surname><given-names>Salvo Danilo</given-names></name><xref ref-type="aff" rid="af1-brainsci-09-00172">1</xref></contrib><contrib contrib-type="author"><name><surname>Mazzon</surname><given-names>Emanuela</given-names></name><xref ref-type="aff" rid="af2-brainsci-09-00172">2</xref></contrib><contrib contrib-type="author"><name><surname>Basile</surname><given-names>Maria Sofia</given-names></name><xref ref-type="aff" rid="af1-brainsci-09-00172">1</xref></contrib><contrib contrib-type="author"><name><surname>Cavalli</surname><given-names>Eugenio</given-names></name><xref ref-type="aff" rid="af2-brainsci-09-00172">2</xref></contrib><contrib contrib-type="author"><name><surname>Bramanti</surname><given-names>Placido</given-names></name><xref ref-type="aff" rid="af2-brainsci-09-00172">2</xref></contrib><contrib contrib-type="author"><name><surname>Nania</surname><given-names>Riccardo</given-names></name><xref ref-type="aff" rid="af1-brainsci-09-00172">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6694-1992</contrib-id><name><surname>Fagone</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="af1-brainsci-09-00172">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4570-8462</contrib-id><name><surname>Nicoletti</surname><given-names>Ferdinando</given-names></name><xref ref-type="aff" rid="af1-brainsci-09-00172">1</xref><xref rid="c1-brainsci-09-00172" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Petralia</surname><given-names>Maria Cristina</given-names></name><xref ref-type="aff" rid="af2-brainsci-09-00172">2</xref></contrib></contrib-group><aff id="af1-brainsci-09-00172"><label>1</label>Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123 Catania, Italy</aff><aff id="af2-brainsci-09-00172"><label>2</label>IRCCS Centro Neurolesi Bonino Pulejo, Strada Statale 113, C.da Casazza, 98124 Messina, Italy</aff><author-notes><corresp id="c1-brainsci-09-00172"><label>*</label>Correspondence: <email>ferdinic@unict.it</email>; Tel.: +39-095-478-1270</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2019</year></pub-date><volume>9</volume><issue>7</issue><elocation-id>172</elocation-id><history><date date-type="received"><day>09</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Migraine is a disorder characterized by attacks of monolateral headaches, often accompanied by nausea, vomiting, and photophobia. Around 30% of patients also report aura symptoms. The cause of the aura is believed to be related to the cortical spreading depression (CSD), a wave of neuronal and glial depolarization originating in the occipital cortex, followed by temporary neuronal silencing. During a migraine attack, increased expression of inflammatory mediators, along with a decrease in the expression of anti-inflammatory genes, have been observed. The aim of this study was to evaluate the expression of inflammatory genes, in particular that of IL-1 receptor antagonist <italic>(IL-1RN)</italic>, following CSD in a mouse model of familial hemiplegic migraine type 1 (FHM-1). We show here that the expression of <italic>IL-1RN</italic> was upregulated after the CSD, suggesting a possible attempt to modulate the inflammatory response. This study allows researchers to better understand the development of the disease and aids in the search for new therapeutic strategies in migraine.</p></abstract><kwd-group><kwd>migraine</kwd><kwd>IL-1RN</kwd><kwd>cortical spreading depression</kwd><kwd>mouse model</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-brainsci-09-00172"><title>1. Introduction</title><p>Migraine is a common neurological disease, representing the fourth cause of years lived with disability (YLDs) for women, and the eighth for men [<xref rid="B1-brainsci-09-00172" ref-type="bibr">1</xref>,<xref rid="B2-brainsci-09-00172" ref-type="bibr">2</xref>,<xref rid="B3-brainsci-09-00172" ref-type="bibr">3</xref>]. It is characterized by attacks of monolateral headaches, associated with nausea as well as phono- and photophobia [<xref rid="B4-brainsci-09-00172" ref-type="bibr">4</xref>]. Around 30% of patients also report aura symptoms, which are mostly visual. The cause of the aura is believed to be related to the cortical spreading depression (CSD), a self-propagating wave of cellular depolarization from the occipital cortex, followed by a transitory neuronal silencing [<xref rid="B5-brainsci-09-00172" ref-type="bibr">5</xref>,<xref rid="B6-brainsci-09-00172" ref-type="bibr">6</xref>]. </p><p>The manifestation of these attacks depends on a genetic predisposition, associated to environmental stimuli such as stress, hormones, meteorological changes, and sleep disorders. For this reason, it is difficult to identify the etiology and physiopathogenesis of migraine. Recent evidence also suggests that immunoinflammatory events may also play a role in the pathogenesis of migraine [<xref rid="B7-brainsci-09-00172" ref-type="bibr">7</xref>,<xref rid="B8-brainsci-09-00172" ref-type="bibr">8</xref>]. </p><p>In particular, much attention has been given to the role of immune-system hormones, named cytokines, to the pathogenesis of migraine [<xref rid="B9-brainsci-09-00172" ref-type="bibr">9</xref>].</p><p>Based on preclinical and clinical studies, the cytokines have been divided into at least five subfamilies: the proinflammatory Th1/Th17 cytokines, the anti-inflammatory Th2/Th3 cytokines, and the Th9 cytokine, represented by IL-9 [<xref rid="B10-brainsci-09-00172" ref-type="bibr">10</xref>,<xref rid="B11-brainsci-09-00172" ref-type="bibr">11</xref>,<xref rid="B12-brainsci-09-00172" ref-type="bibr">12</xref>].</p><p>It has been shown that Th1 and Th17 cytokines primarily exert proinflammatory effects. They are produced by M1 macrophages, Th1 and Th17 cells, and include&#x02014;among others&#x02014;IL-1, TNF-alpha, IFN-gamma, IL-12, IL-18, IL-22, IL-23, and IL-17. They may contribute to the initiation of cell-mediated autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and Guillain-Barr&#x000e9; syndrome [<xref rid="B10-brainsci-09-00172" ref-type="bibr">10</xref>,<xref rid="B11-brainsci-09-00172" ref-type="bibr">11</xref>,<xref rid="B13-brainsci-09-00172" ref-type="bibr">13</xref>].</p><p>Anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-13 IL-35, TGF-beta) are primarily produced from M2 macrophages and Th2 and Th3 cells. They decrease Th1- and Th17-mediated immunoinflammatory events, and are implicated in IgE-mediated allergic diseases and eosinophil-mediated pathologies [<xref rid="B14-brainsci-09-00172" ref-type="bibr">14</xref>,<xref rid="B15-brainsci-09-00172" ref-type="bibr">15</xref>,<xref rid="B16-brainsci-09-00172" ref-type="bibr">16</xref>,<xref rid="B17-brainsci-09-00172" ref-type="bibr">17</xref>]. </p><p>Sometimes, such as in the case of systemic lupus erythematosus, it seems that the combined action of Th1/Th2 cytokines may be simultaneously involved in the pathogenesis of the disease [<xref rid="B18-brainsci-09-00172" ref-type="bibr">18</xref>]. The precise role of IL-9 in regulation of the immune responses is less well-defined, and is receiving a great deal of attention [<xref rid="B12-brainsci-09-00172" ref-type="bibr">12</xref>]. </p><p>In addition, the function of cytokines is also finely regulated by endogenous antagonists, which have been described for most cytokines, such as soluble receptors, anti-cytokine autoantibody, and for IL-1, the IL-1 receptor antagonist [<xref rid="B19-brainsci-09-00172" ref-type="bibr">19</xref>,<xref rid="B20-brainsci-09-00172" ref-type="bibr">20</xref>,<xref rid="B21-brainsci-09-00172" ref-type="bibr">21</xref>]. These endogenous antagonists are usually produced during immune responses, and serve to control and downregulate excessive signaling of the cytokine through binding with its functionally active receptors expressed on the surface of the target cells. For example, we have shown that blood levels of IL-1ra are augmented during attacks of multiple sclerosis and are further augmented from the treatment of the patients with IFN-beta [<xref rid="B22-brainsci-09-00172" ref-type="bibr">22</xref>].</p><p>Cytokines have recently been associated to the etiology of migraine, even if conflicting results have been found [<xref rid="B23-brainsci-09-00172" ref-type="bibr">23</xref>,<xref rid="B24-brainsci-09-00172" ref-type="bibr">24</xref>,<xref rid="B25-brainsci-09-00172" ref-type="bibr">25</xref>]. The association between migraine and the interleukin-1 receptor antagonist variable number tandem repeat (IL-1RN VNTR) has previously been investigated, but no statistically significant differences were discovered [<xref rid="B26-brainsci-09-00172" ref-type="bibr">26</xref>].</p><p>A cross-talk between neurons and immune cells has also been reported, which may contribute to the generation of the pain [<xref rid="B27-brainsci-09-00172" ref-type="bibr">27</xref>]. Indeed, activated macrophages and other non-neuronal cells might induce a meningeal &#x02018;&#x02018;sterile inflammation&#x02019;&#x02019; [<xref rid="B28-brainsci-09-00172" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-09-00172" ref-type="bibr">29</xref>], contributing to the pain symptoms [<xref rid="B30-brainsci-09-00172" ref-type="bibr">30</xref>,<xref rid="B31-brainsci-09-00172" ref-type="bibr">31</xref>]. Furthermore, it has been reported that inflammation in the trigeminal nerve territory is often observed during migraine attacks [<xref rid="B32-brainsci-09-00172" ref-type="bibr">32</xref>], so the acute administration of corticosteroids has been tested to block pain [<xref rid="B33-brainsci-09-00172" ref-type="bibr">33</xref>]. </p><p>Familial hemiplegic migraine type 1 (FHM-1) is a monogenic type of migraine with aura caused by mutations in the <italic>CACNA1A</italic> gene which determine an alteration of the passage of Ca<sup>2+</sup> ions in the cerebral cortex [<xref rid="B34-brainsci-09-00172" ref-type="bibr">34</xref>,<xref rid="B35-brainsci-09-00172" ref-type="bibr">35</xref>]. The FHM mouse model, generated by introducing the R192Q mutation into the endogenous <italic>CACNA1A</italic> gene [<xref rid="B36-brainsci-09-00172" ref-type="bibr">36</xref>], is used to study the physiopathology of FHM-1 [<xref rid="B37-brainsci-09-00172" ref-type="bibr">37</xref>,<xref rid="B38-brainsci-09-00172" ref-type="bibr">38</xref>]. R192Q KI mice have increased neuronal Ca<sup>2+</sup> influx and augmented glutamate release [<xref rid="B39-brainsci-09-00172" ref-type="bibr">39</xref>], which may explain the increased susceptibility to CSD [<xref rid="B36-brainsci-09-00172" ref-type="bibr">36</xref>,<xref rid="B39-brainsci-09-00172" ref-type="bibr">39</xref>]. Data from animal models have shown that CSD is able to activate meningeal trigeminovascular neurons, generating the sensation of pain [<xref rid="B40-brainsci-09-00172" ref-type="bibr">40</xref>,<xref rid="B41-brainsci-09-00172" ref-type="bibr">41</xref>,<xref rid="B42-brainsci-09-00172" ref-type="bibr">42</xref>]. </p><p>The aim of the present study was to determine the expression of inflammatory genes and in particular that of IL-1 receptor antagonist (<italic>IL-1RN</italic>) upon CSD, in a murine model of FHM1. </p></sec><sec id="sec2-brainsci-09-00172"><title>2. Materials and Methods </title><sec id="sec2dot1-brainsci-09-00172"><title>2.1. Dataset Selection and Analysis</title><p>In order to evaluate the brain expression levels of <italic>IL-1RN</italic> following CSD, we interrogated the GSE67933 dataset, obtained from the GEO dataset [<xref rid="B43-brainsci-09-00172" ref-type="bibr">43</xref>]. The dataset included whole-genome transcriptomic data from wild-type (WT) mice and transgenic mice carrying the CACNA1A R192Q missense mutation (FHM1 R192Q mice). Gene expression profiles were obtained from cortical tissue of FHM1 R192Q and control mice, 24 h after experimentally induced CSD [<xref rid="B44-brainsci-09-00172" ref-type="bibr">44</xref>]. Briefly, CSD was induced by seven applications of a cotton pellet soaked in 300 mM KCl on the dura overlaying the occipital cortex, while in sham animals 300 mM NaCl was applied instead of KCl [<xref rid="B44-brainsci-09-00172" ref-type="bibr">44</xref>]. Deep SAGE sequencing was used to generate the expression profiles, and the data were normalized using the trimmed mean of M-values (TMM) method.</p><p>Functionally correlated genes were obtained using the web-based software STRING [<xref rid="B45-brainsci-09-00172" ref-type="bibr">45</xref>] and visualized as a gene network. Relationships of genes in the network were defined in terms of co-expression, text-mining, biochemical data, curated pathway, and protein&#x02013;protein interactions. The confidence cut-off for showing interaction links was set as medium (0.4) and the maximum number of interactors in the first shell was set at 50. </p><p>Heatmapper [<xref rid="B46-brainsci-09-00172" ref-type="bibr">46</xref>] software was used to generate the expression heatmap of the functional related genes to <italic>IL-1RN</italic> and to perform hierarchical clustering of genes. Average linkage was used as clustering method and Euclidean distance as distance measurement. </p><p>Co-expression analysis was carried out using the CoExpress software [<xref rid="B47-brainsci-09-00172" ref-type="bibr">47</xref>], and gene enrichment for biological processes (BPs) and molecular functions (MFs) was performed using the web-based utility DAVID version 6.8 [<xref rid="B48-brainsci-09-00172" ref-type="bibr">48</xref>].</p></sec><sec id="sec2dot2-brainsci-09-00172"><title>2.2. Statistical Analysis</title><p>Data are shown as mean &#x000b1; standard deviation. Differences in <italic>IL-1RN</italic> expression among the experimental groups were evaluated by ANOVA (Student&#x02019;s <italic>t</italic>-test) with Bonferroni post-hoc test. Correlation analysis was performed using the Pearson&#x02019;s correlation test. Statistical analysis was performed using IBM SPSS Statistics 23 [<xref rid="B49-brainsci-09-00172" ref-type="bibr">49</xref>] and GraphPad Prism 8.0.2 [<xref rid="B50-brainsci-09-00172" ref-type="bibr">50</xref>]. </p></sec></sec><sec sec-type="results" id="sec3-brainsci-09-00172"><title>3. Results</title><sec id="sec3dot1-brainsci-09-00172"><title>3.1. IL-1RN Expression after CSD</title><p>The GSE67933 dataset was used to determine the expression levels of <italic>IL-1RN</italic> following CSD in a murine model of FHM1 (<xref ref-type="fig" rid="brainsci-09-00172-f001">Figure 1</xref>). No significant differences in <italic>IL-1RN</italic> levels were observed in FHM1 R192Q vs. wild-type (WT) cortex at basal condition (sham). No significant differences in <italic>IL-1RN</italic> expression were observed following CSD induction in WT mice as compared to sham-operated WT mice. Significantly higher levels of <italic>IL-1RN</italic> were observed upon CSD in FHM1 R192Q animals as compared to sham-operated mice (<italic>p</italic> &#x0003c; 0.0001) (<xref ref-type="fig" rid="brainsci-09-00172-f001">Figure 1</xref>). </p></sec><sec id="sec3dot2-brainsci-09-00172"><title>3.2. Identification of Genes Functionally Related to IL-1RN</title><p>We then evaluated the expression of the genes functionally related to <italic>IL-1RN</italic> (<xref ref-type="fig" rid="brainsci-09-00172-f002">Figure 2</xref>A and <xref ref-type="app" rid="app1-brainsci-09-00172">Supplementary File 1</xref>). As shown in <xref ref-type="fig" rid="brainsci-09-00172-f002">Figure 2</xref> and <xref rid="brainsci-09-00172-t001" ref-type="table">Table 1</xref>, several of the genes identified were found to be modulated in the cortex from FHM1 R192Q mice subjected to CSD (<xref ref-type="fig" rid="brainsci-09-00172-f002">Figure 2</xref>B). Among them, a significant upregulation of <italic>IL-6</italic>, <italic>TNF</italic>, <italic>TLR2</italic>, and <italic>TLR4</italic> could be observed in FHM1 R192Q mice upon CSD as compared to FHM1 R192Q sham-operated mice (<xref ref-type="app" rid="app1-brainsci-09-00172">Supplementary Table S1</xref>). Moreover, as compared to CSD-induced WT mice, FHM1 R192Q mice upon CSD expressed lower levels of <italic>IL-18, IL-10</italic>, <italic>IL-2</italic>, <italic>IL-4</italic>, and <italic>IL-13</italic>, and significantly higher levels of <italic>IFNK</italic>, <italic>IL-17A</italic>, <italic>SOCS3</italic>, and of several members of the chemokine/chemokine receptor family (<italic>CCL2</italic>, <italic>CXCL2</italic>, <italic>CXCL10</italic>, <italic>CCL4</italic>, <italic>CCL7</italic>, <italic>CXCL1</italic>, <italic>CXCL3</italic>, <italic>CCR1</italic>, <italic>CXCL9</italic>).</p></sec><sec id="sec3dot3-brainsci-09-00172"><title>3.3. Identification of Genes Statistically Correlated to IL-1RN</title><p>We found 927 genes statistically correlated to <italic>IL-1RN</italic> in CDS-induced FHM1 R192Q mice, considering as threshold a Pearson correlation coefficient (r) &#x0003e; 0.95 and a <italic>p</italic>-value &#x0003c; 0.05. The top 20 statistically significant correlated genes are presented in <xref rid="brainsci-09-00172-t001" ref-type="table">Table 1</xref>. Gene Ontology for biological processes (BPs) revealed a significant enrichment of genes involved in the &#x0201c;G-protein coupled receptor signaling pathway&#x0201d; (<italic>p</italic> &#x0003c; 0.0001), &#x0201c;sensory perception of smell&#x0201d; (<italic>p</italic> &#x0003c; 0.0001) and &#x0201c;inflammatory response&#x0201d; (<italic>p</italic> &#x0003c; 0.0001) (<xref ref-type="fig" rid="brainsci-09-00172-f003">Figure 3</xref>A). The top enriched molecular functions (MFs) were: &#x0201c;olfactory receptor activity&#x0201d; (<italic>p</italic> &#x0003c; 0.0001), G-protein coupled receptor activity (<italic>p</italic> &#x0003c; 0.0001) and &#x0201c;odorant binding&#x0201d; (<italic>p</italic> &#x0003c; 0.0001) (<xref ref-type="fig" rid="brainsci-09-00172-f003">Figure 3</xref>B).</p></sec></sec><sec sec-type="discussion" id="sec4-brainsci-09-00172"><title>4. Discussion</title><p>Many studies have shown a relationship between migraine and inflammation [<xref rid="B51-brainsci-09-00172" ref-type="bibr">51</xref>,<xref rid="B52-brainsci-09-00172" ref-type="bibr">52</xref>]. Neurogenic inflammation is characterized by the release of vasoactive neuropeptides from nociceptive sensory nerve terminals, including calcitonin gene-related peptide (CGRP), substance P (SP), and neurokinin A. These peptides lead to the dilatation of vessels, with increased permeability and consequent exudation of fluids, plasma proteins, leukocyte extravasation, and mast cell degranulation [<xref rid="B51-brainsci-09-00172" ref-type="bibr">51</xref>]. In particular, it has been proposed that migraine may be associated with an inflammation of the meninges, especially the dura mater. During a migraine attack, an idiopathic activation of the trigeminal sensory afferents is thought to facilitate the nociceptive transmission to the central nervous system (CNS). Accordingly, inhibition of the dural neurogenic inflammation with molecules able to inhibit the pathways involved in the activation and sensitization of trigeminovascular neurons&#x02014;at both their central and peripheral perivascular nerve endings&#x02014;have been tested as potential therapeutic strategies in the treatment of migraine [<xref rid="B51-brainsci-09-00172" ref-type="bibr">51</xref>].</p><p>The main current therapy for migraine is based on triptans [<xref rid="B53-brainsci-09-00172" ref-type="bibr">53</xref>], which have been shown to attenuate the release of neuropeptides and neurogenic plasma protein extravasation. These findings provide support for the validity of using animal models of neurogenic inflammation to investigate putative etiopathogenic mechanisms in migraine. </p><p>During the interictal period (headache-free days), independent studies have demonstrated increased peripheral levels of the pro-inflammatory cytokines IL-1&#x003b2;, IL-6, and TNF-&#x003b1;, and of the chemokine IL-8. On the other hand, the levels of the anti-inflammatory cytokine IL-10 have been found to be either unaltered or reduced in migraine patients as compared to healthy controls. Moreover, during a migraine attack, the serum concentrations of IL-1&#x003b2;, IL-6, IL-8, and TNF-&#x003b1; increase, alongside the levels of IL-10; in contrast, the type 2 cytokines IL-4 and IL-5 decrease [<xref rid="B54-brainsci-09-00172" ref-type="bibr">54</xref>]. Interestingly, migraine seems to be associated with immune-inflammatory and atopic diseases sustained by both Th1- or Th2-dominant responses, such as Inflammatory Bowel Disease and asthma [<xref rid="B54-brainsci-09-00172" ref-type="bibr">54</xref>]. </p><p>Many studies have already observed that CSD induces the upregulation of several pro-inflammatory cytokines [<xref rid="B6-brainsci-09-00172" ref-type="bibr">6</xref>,<xref rid="B40-brainsci-09-00172" ref-type="bibr">40</xref>,<xref rid="B44-brainsci-09-00172" ref-type="bibr">44</xref>,<xref rid="B55-brainsci-09-00172" ref-type="bibr">55</xref>,<xref rid="B56-brainsci-09-00172" ref-type="bibr">56</xref>,<xref rid="B57-brainsci-09-00172" ref-type="bibr">57</xref>,<xref rid="B58-brainsci-09-00172" ref-type="bibr">58</xref>]. In the present study, we evaluated the expression of <italic>IL-1RN</italic> during CSD in a model of FMH1 by using a publicly available deep SAGE dataset. The use of whole-genome expression data has been extensively used for the identification of novel pathogenic pathways and therapeutic targets in a variety of diseases (e.g., autoimmunity [<xref rid="B59-brainsci-09-00172" ref-type="bibr">59</xref>,<xref rid="B60-brainsci-09-00172" ref-type="bibr">60</xref>,<xref rid="B61-brainsci-09-00172" ref-type="bibr">61</xref>,<xref rid="B62-brainsci-09-00172" ref-type="bibr">62</xref>], cancer [<xref rid="B63-brainsci-09-00172" ref-type="bibr">63</xref>,<xref rid="B64-brainsci-09-00172" ref-type="bibr">64</xref>,<xref rid="B65-brainsci-09-00172" ref-type="bibr">65</xref>,<xref rid="B66-brainsci-09-00172" ref-type="bibr">66</xref>], hepatic [<xref rid="B67-brainsci-09-00172" ref-type="bibr">67</xref>,<xref rid="B68-brainsci-09-00172" ref-type="bibr">68</xref>], neurodegenerative, and infectious diseases [<xref rid="B69-brainsci-09-00172" ref-type="bibr">69</xref>]). </p><p>The protein encoded by <italic>IL-1RN</italic> is a soluble factor that regulates the inflammatory response, as reported by various studies [<xref rid="B21-brainsci-09-00172" ref-type="bibr">21</xref>,<xref rid="B22-brainsci-09-00172" ref-type="bibr">22</xref>,<xref rid="B70-brainsci-09-00172" ref-type="bibr">70</xref>,<xref rid="B71-brainsci-09-00172" ref-type="bibr">71</xref>]. However, its role in migraine is still largely unexplored. In a previous study, significantly higher levels of <italic>IL-1RN</italic>, <italic>TGF-&#x003b2;1</italic>, and <italic>MCP-1</italic> in the cerebrospinal fluid of migraine patients as compared to controls were found [<xref rid="B72-brainsci-09-00172" ref-type="bibr">72</xref>].</p><p>Unlike <italic>IL-2</italic>, <italic>IL-4</italic>, <italic>IL-10</italic>, and <italic>IL-13</italic>, the expression of <italic>IL-1RN</italic> and <italic>IL-6</italic> was higher in the brains of FHM1 R192Q mutant mice than in WT mice, probably due to an alteration in Ca<sup>2+</sup> ion channels. We can speculate that these molecules may exert a homeostatic role aimed at counteracting ongoing immunoinflammatory events. Even if the precise biological mechanisms by which IL-1RN production is increased is not known, it could be explained by an induction promoted by both IL-6 [<xref rid="B73-brainsci-09-00172" ref-type="bibr">73</xref>] and IFN-&#x003b1; [<xref rid="B74-brainsci-09-00172" ref-type="bibr">74</xref>]. Indeed, a role for the IFN pathway in migraine has been described [<xref rid="B44-brainsci-09-00172" ref-type="bibr">44</xref>]. We may speculate that compensatory mechanisms may be working constantly in migraine patients via the reciprocal regulation of pro- and anti-inflammatory factors, leading to Th1-dominant responses and the consequent effects associated with these cytokines. Moreover, we found an important increase in several members of the chemokine/chemokine receptor family in FHM1 R192Q, which could contribute to the vasodilatation and to the swelling mechanism underlying migraine and nasal congestion, which represents one of the most common symptoms [<xref rid="B75-brainsci-09-00172" ref-type="bibr">75</xref>]. </p><p>The role of inflammation in migraine is further supported by the therapeutic effects of non-steroidal anti-inflammatory drugs (NSAIDs), currently recommended as the first-line medications for acute migraine attacks, as they improve both pain and breathing [<xref rid="B76-brainsci-09-00172" ref-type="bibr">76</xref>,<xref rid="B77-brainsci-09-00172" ref-type="bibr">77</xref>]. Recently, monoclonal antibodies targeting the CGRP pathway (i.e. fremanezumab, eptinezumab, and galcanezumab) have also been tested in both chronic and episodic migraine, and were shown to improve migraine-associated symptoms, quality of life, and disability, and to reduce monthly migraine days [<xref rid="B78-brainsci-09-00172" ref-type="bibr">78</xref>,<xref rid="B79-brainsci-09-00172" ref-type="bibr">79</xref>,<xref rid="B80-brainsci-09-00172" ref-type="bibr">80</xref>,<xref rid="B81-brainsci-09-00172" ref-type="bibr">81</xref>].</p><p>This study may set the basis for new therapeutic strategies for the treatment of migraine, such as anakinra [<xref rid="B82-brainsci-09-00172" ref-type="bibr">82</xref>]. Anakinra is a recombinant nonglycosylated analogue of the human IL-1RN which competitively blocks the binding of IL-1&#x000df; and IL-1&#x003b1; to the IL-1 receptors. Anakinra was approved by the Food and Drug Administration (FDA) in 2012 for chronic infantile neurological cutaneous and articular syndrome (CINCA) and in 2013 by the European Medicines Agency (EMA) for all subtypes of cryopyrin-associated periodic syndrome (CAPS). In nonhuman primates, anakinra has been shown to be able to cross the blood&#x02013;brain barrier in a dose-dependent manner. Therefore, a direct anti-inflammatory action in the CNS is plausible [<xref rid="B83-brainsci-09-00172" ref-type="bibr">83</xref>]. Although only marginally related to migraine, a recent prospective, open-label, long-term study in 43 patients with severe cryopyrin-associated periodic syndromes (CAPS) demonstrated that anakinra treatment significantly decreased central nervous system inflammation and headaches in pediatric patients.</p></sec><sec sec-type="conclusions" id="sec5-brainsci-09-00172"><title>5. Conclusions</title><p>Little is known about the etiology and physiopathogenesis of migraine, but a large body of evidence shows a relationship with inflammation. In this paper, we show the gene expression of pro- and anti-inflammatory cytokines in a mouse migraine model. In particular, we focus on the expression of <italic>IL-1RN</italic>, which appears to be over-expressed after the CSD, suggesting a possible attempt to modulate the inflammatory response. This study may be the first one that allows a better understanding of the development of the disease and may aid in the search for new therapeutic strategies in migraine.</p></sec></body><back><app-group><app id="app1-brainsci-09-00172"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2076-3425/9/7/172/s1">https://www.mdpi.com/2076-3425/9/7/172/s1</uri>, File 1: Genes functionally related to <italic>IL1RN</italic>, Table S1: Multiple comparison.</p><supplementary-material content-type="local-data" id="brainsci-09-00172-s001"><media xlink:href="brainsci-09-00172-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.D.L., E.M., F.N, P.F., M.C.P.; methodology, S.D.L., P.F., F.N.; formal analysis, S.D.L., P.F., R.N.; writing&#x02014;original draft preparation, S.D.L., E.C. and M.S.B.; writing&#x02014;review and editing, E.M., M.S.B., F.N., and M.C.P.; project administration, E.M., P.B., F.N.; funding acquisition, E.M., P.B., and F.N. All authors read and approved the final version of the manuscript.</p></notes><notes><title>Funding</title><p>This study was supported by current research funds 2018 of IRCCS Centro Neurolesi &#x0201c;Bonino Pulejo&#x0201d;, Messina-Italy.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><notes><title>Sample Availability</title><p>Data are available from the Gene Expression Ombnibus Database.</p></notes><ref-list><title>References</title><ref id="B1-brainsci-09-00172"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stovner</surname><given-names>L.J.</given-names></name><name><surname>Hagen</surname><given-names>K.</given-names></name><name><surname>Jensen</surname><given-names>R.</given-names></name><name><surname>Katsarava</surname><given-names>Z.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Scher</surname><given-names>A.I.</given-names></name><name><surname>Steiner</surname><given-names>T.J.</given-names></name><name><surname>Zwart</surname><given-names>J.A.</given-names></name></person-group><article-title>The global burden of headache: A documentation of headache prevalence and disability worldwide</article-title><source>Cephalalgia</source><year>2007</year><volume>27</volume><fpage>193</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01288.x</pub-id><?supplied-pmid 17381554?><pub-id pub-id-type="pmid">17381554</pub-id></element-citation></ref><ref id="B2-brainsci-09-00172"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetvik</surname><given-names>K.G.</given-names></name><name><surname>MacGregor</surname><given-names>E.A.</given-names></name></person-group><article-title>Sex differences in the epidemiology, clinical features, and pathophysiology of migraine</article-title><source>Lancet Neurol.</source><year>2017</year><volume>16</volume><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(16)30293-9</pub-id><pub-id pub-id-type="pmid">27836433</pub-id></element-citation></ref><ref id="B3-brainsci-09-00172"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>M.B.</given-names></name><name><surname>Rasmussen</surname><given-names>B.K.</given-names></name><name><surname>Thorvaldsen</surname><given-names>P.</given-names></name><name><surname>Olesen</surname><given-names>J.</given-names></name></person-group><article-title>Prevalence and sex-ratio of the subtypes of migraine</article-title><source>Int. J. Epidemiol.</source><year>1995</year><pub-id pub-id-type="doi">10.1093/ije/24.3.612</pub-id><?supplied-pmid 7672904?><pub-id pub-id-type="pmid">7672904</pub-id></element-citation></ref><ref id="B4-brainsci-09-00172"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Committee of the International Headache Society (IHS)</collab></person-group><article-title>The International Classification of Headache Disorders, 3rd edition (beta version)</article-title><source>Cephalalgia</source><year>2013</year><pub-id pub-id-type="doi">10.1177/0333102413485658</pub-id></element-citation></ref><ref id="B5-brainsci-09-00172"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>M.</given-names></name></person-group><article-title>Pathophysiology of the migraine aura: The spreading depression theory</article-title><source>Brain</source><year>1994</year><volume>117</volume><issue-part>Pt 1</issue-part><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1093/brain/117.1.199</pub-id><pub-id pub-id-type="pmid">7908596</pub-id></element-citation></ref><ref id="B6-brainsci-09-00172"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Kataoka</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>Y.</given-names></name></person-group><article-title>Role of cortical spreading depression in the pathophysiology of migraine</article-title><source>Neurosci. Bull.</source><year>2014</year><volume>30</volume><fpage>812</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1007/s12264-014-1471-y</pub-id><?supplied-pmid 25260797?><pub-id pub-id-type="pmid">25260797</pub-id></element-citation></ref><ref id="B7-brainsci-09-00172"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longoni</surname><given-names>M.</given-names></name><name><surname>Ferrarese</surname><given-names>C.</given-names></name></person-group><article-title>Inflammation and excitotoxicity: Role in migraine pathogenesis</article-title><source>Neurol. Sci.</source><year>2006</year><pub-id pub-id-type="doi">10.1007/s10072-006-0582-2</pub-id></element-citation></ref><ref id="B8-brainsci-09-00172"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edvinsson</surname><given-names>L.</given-names></name><name><surname>Haanes</surname><given-names>K.A.</given-names></name><name><surname>Warfvinge</surname><given-names>K.</given-names></name></person-group><article-title>Does inflammation have a role in migraine?</article-title><source>Nat. Rev. Neurol.</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s41582-019-0216-y</pub-id></element-citation></ref><ref id="B9-brainsci-09-00172"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacabelos</surname><given-names>R.</given-names></name><name><surname>Torrellas</surname><given-names>C.</given-names></name><name><surname>Fern&#x000e1;ndez-Novoa</surname><given-names>L.</given-names></name><name><surname>L&#x000f3;pez-Mu&#x000f1;oz</surname><given-names>F.</given-names></name></person-group><article-title>Histamine and Immune Biomarkers in CNS Disorders</article-title><source>Mediat. Inflamm.</source><year>2016</year><volume>2016</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2016/1924603</pub-id></element-citation></ref><ref id="B10-brainsci-09-00172"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roeleveld</surname><given-names>D.M.</given-names></name><name><surname>Koenders</surname><given-names>M.I.</given-names></name></person-group><article-title>The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy</article-title><source>Cytokine</source><year>2015</year><volume>74</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2014.10.006</pub-id><pub-id pub-id-type="pmid">25466295</pub-id></element-citation></ref><ref id="B11-brainsci-09-00172"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.-L.</given-names></name><name><surname>Zheng</surname><given-names>X.-Y.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>Th1/Th2/Th17/Treg cytokines in Guillain&#x02013;Barr&#x000e9; syndrome and experimental autoimmune neuritis</article-title><source>Cytokine Growth Factor Rev.</source><year>2013</year><volume>24</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2013.05.005</pub-id><?supplied-pmid 23791985?><pub-id pub-id-type="pmid">23791985</pub-id></element-citation></ref><ref id="B12-brainsci-09-00172"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S.</given-names></name><name><surname>Kubatzky</surname><given-names>K.F.</given-names></name><name><surname>Mitra</surname><given-names>D.K.</given-names></name></person-group><article-title>An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>2113</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20092113</pub-id><?supplied-pmid 31035677?><pub-id pub-id-type="pmid">31035677</pub-id></element-citation></ref><ref id="B13-brainsci-09-00172"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dujmovic</surname><given-names>I.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Pekmezovic</surname><given-names>T.</given-names></name><name><surname>Quattrocchi</surname><given-names>C.</given-names></name><name><surname>Mesaros</surname><given-names>S.</given-names></name><name><surname>Stojsavljevic</surname><given-names>N.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Drulovic</surname><given-names>J.</given-names></name></person-group><article-title>The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy</article-title><source>J. Neuroimmunol.</source><year>2009</year><volume>207</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.11.004</pub-id><?supplied-pmid 19162335?><pub-id pub-id-type="pmid">19162335</pub-id></element-citation></ref><ref id="B14-brainsci-09-00172"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayakannu</surname><given-names>R.</given-names></name><name><surname>Abdullah</surname><given-names>N.A.</given-names></name><name><surname>Radhakrishnan</surname><given-names>A.K.</given-names></name><name><surname>Lechimi Raj</surname><given-names>V.</given-names></name><name><surname>Liam</surname><given-names>C.K.</given-names></name></person-group><article-title>Relationship between various cytokines implicated in asthma</article-title><source>Hum. Immunol.</source><year>2019</year><pub-id pub-id-type="doi">10.1016/j.humimm.2019.04.018</pub-id></element-citation></ref><ref id="B15-brainsci-09-00172"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Mancuso</surname><given-names>G.</given-names></name><name><surname>Cusumano</surname><given-names>V.</given-names></name><name><surname>Di Marco</surname><given-names>R.</given-names></name><name><surname>Zaccone</surname><given-names>P.</given-names></name><name><surname>Bendtzen</surname><given-names>K.</given-names></name><name><surname>Teti</surname><given-names>G.</given-names></name></person-group><article-title>Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13</article-title><source>Eur. J. Immunol.</source><year>1997</year><volume>27</volume><fpage>1580</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1002/eji.1830270639</pub-id><?supplied-pmid 9209514?><pub-id pub-id-type="pmid">9209514</pub-id></element-citation></ref><ref id="B16-brainsci-09-00172"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>T.F.</given-names></name><name><surname>Hammer</surname><given-names>L.</given-names></name><name><surname>Furtado</surname><given-names>S.</given-names></name><name><surname>Mathiowitz</surname><given-names>E.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Egilmez</surname><given-names>N.K.</given-names></name><name><surname>Auci</surname><given-names>D.L.</given-names></name></person-group><article-title>Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2015</year><volume>9</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjv089</pub-id><pub-id pub-id-type="pmid">25987350</pub-id></element-citation></ref><ref id="B17-brainsci-09-00172"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Di Marco</surname><given-names>R.</given-names></name><name><surname>Patti</surname><given-names>F.</given-names></name><name><surname>Reggio</surname><given-names>E.</given-names></name><name><surname>Nicoletti</surname><given-names>A.</given-names></name><name><surname>Zaccone</surname><given-names>P.</given-names></name><name><surname>Stivala</surname><given-names>F.</given-names></name><name><surname>Meroni</surname><given-names>P.L.</given-names></name><name><surname>Reggio</surname><given-names>A.</given-names></name></person-group><article-title>Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b)</article-title><source>Clin. Exp. Immunol.</source><year>1998</year><volume>113</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.1998.00604.x</pub-id><pub-id pub-id-type="pmid">9697990</pub-id></element-citation></ref><ref id="B18-brainsci-09-00172"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barcellini</surname><given-names>W.</given-names></name><name><surname>Rizzardi</surname><given-names>G.P.</given-names></name><name><surname>Borghi</surname><given-names>M.O.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Fain</surname><given-names>C.</given-names></name><name><surname>Del Papa</surname><given-names>N.</given-names></name><name><surname>Meroni</surname><given-names>P.L.</given-names></name></person-group><article-title>In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: Lack of relationship with clinical disease activity</article-title><source>Lupus</source><year>1996</year><volume>5</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1177/096120339600500209</pub-id><pub-id pub-id-type="pmid">8743127</pub-id></element-citation></ref><ref id="B19-brainsci-09-00172"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiotti</surname><given-names>N.</given-names></name><name><surname>Giansante</surname><given-names>C.</given-names></name><name><surname>Ponte</surname><given-names>E.</given-names></name><name><surname>Delbello</surname><given-names>C.</given-names></name><name><surname>Calabrese</surname><given-names>S.</given-names></name><name><surname>Zacchi</surname><given-names>T.</given-names></name><name><surname>Dobrina</surname><given-names>A.</given-names></name><name><surname>Guarnieri</surname><given-names>G.</given-names></name></person-group><article-title>Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease</article-title><source>Atherosclerosis</source><year>1999</year><volume>145</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(99)00013-1</pub-id><pub-id pub-id-type="pmid">10428295</pub-id></element-citation></ref><ref id="B20-brainsci-09-00172"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>C.H.</given-names></name><name><surname>Bendtzen</surname><given-names>K.</given-names></name></person-group><article-title>Immunoregulation by Naturally Occurring and Disease-Associated Autoantibodies: Binding to cytokines and their role in regulation of T-cell responses</article-title><source>Adv. Exp. Med. Biol.</source><year>2012</year><volume>750</volume><fpage>116</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-3461-0_9</pub-id><pub-id pub-id-type="pmid">22903670</pub-id></element-citation></ref><ref id="B21-brainsci-09-00172"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arend</surname><given-names>W.P.</given-names></name><name><surname>Malyak</surname><given-names>M.</given-names></name><name><surname>Guthridge</surname><given-names>C.J.</given-names></name><name><surname>Gabay</surname><given-names>C.</given-names></name></person-group><article-title>INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology</article-title><source>Annu. Rev. Immunol.</source><year>2002</year><pub-id pub-id-type="doi">10.1146/annurev.immunol.16.1.27</pub-id></element-citation></ref><ref id="B22-brainsci-09-00172"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Patti</surname><given-names>F.</given-names></name><name><surname>Di Marco</surname><given-names>R.</given-names></name><name><surname>Zaccone</surname><given-names>P.</given-names></name><name><surname>Nicoletti</surname><given-names>A.</given-names></name><name><surname>Meroni</surname><given-names>P.L.</given-names></name><name><surname>Reggio</surname><given-names>A.</given-names></name></person-group><article-title>Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-&#x003b2; treatment</article-title><source>Cytokine</source><year>1996</year><pub-id pub-id-type="doi">10.1006/cyto.1996.0054</pub-id></element-citation></ref><ref id="B23-brainsci-09-00172"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname><given-names>F.</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>G.</given-names></name><name><surname>Galloni</surname><given-names>E.</given-names></name><name><surname>Pignatelli</surname><given-names>F.</given-names></name><name><surname>Billo</surname><given-names>G.</given-names></name><name><surname>Alba</surname><given-names>S.</given-names></name><name><surname>Bussone</surname><given-names>G.</given-names></name><name><surname>Toso</surname><given-names>V.</given-names></name></person-group><article-title>Plasma cytokine levels in migraineurs and controls</article-title><source>Headache</source><year>2005</year><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.05135.x</pub-id><?supplied-pmid 15985111?><pub-id pub-id-type="pmid">15985111</pub-id></element-citation></ref><ref id="B24-brainsci-09-00172"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Empl</surname><given-names>M.</given-names></name><name><surname>Sostak</surname><given-names>P.</given-names></name><name><surname>Riedel</surname><given-names>M.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>N.</given-names></name><name><surname>F&#x000f6;rderreuther</surname><given-names>S.</given-names></name><name><surname>Straube</surname><given-names>A.</given-names></name></person-group><article-title>Decreased sTNF-RI in migraine patients?</article-title><source>Cephalalgia</source><year>2003</year><pub-id pub-id-type="doi">10.1046/j.1468-2982.2003.00453.x</pub-id></element-citation></ref><ref id="B25-brainsci-09-00172"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covelli</surname><given-names>V.</given-names></name><name><surname>Munno</surname><given-names>I.</given-names></name><name><surname>Pellegrino</surname><given-names>N.M.</given-names></name><name><surname>Di Venere</surname><given-names>A.</given-names></name><name><surname>Jirillo</surname><given-names>E.</given-names></name><name><surname>Buscaino</surname><given-names>G.A.</given-names></name></person-group><article-title>Exaggerated spontaneous release of tumor necrosis factor-alpha/cachectin in patients with migraine without aura</article-title><source>Acta Neurol. (Napoli)</source><year>1990</year><volume>12</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">2251950</pub-id></element-citation></ref><ref id="B26-brainsci-09-00172"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>I.A.</given-names></name><name><surname>&#x000d6;zge</surname><given-names>A.</given-names></name><name><surname>Erdal</surname><given-names>M.E.</given-names></name><name><surname>Edg&#x000fc;nl&#x000fc;</surname><given-names>T.G.</given-names></name><name><surname>&#x000c7;akmak</surname><given-names>S.E.</given-names></name><name><surname>Yalin</surname><given-names>O.&#x000d6;.</given-names></name></person-group><article-title>Cytokine polymorphism in patients with migraine: Some suggestive clues of migraine and inflammation</article-title><source>Pain Med.</source><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1526-4637.2009.00791.x</pub-id><?supplied-pmid 20113413?><pub-id pub-id-type="pmid">20113413</pub-id></element-citation></ref><ref id="B27-brainsci-09-00172"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaper</surname><given-names>S.D.</given-names></name></person-group><article-title>Nerve growth factor: A neuroimmune crosstalk mediator for all seasons</article-title><source>Immunology</source><year>2017</year><volume>151</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/imm.12717</pub-id><?supplied-pmid 28112808?><pub-id pub-id-type="pmid">28112808</pub-id></element-citation></ref><ref id="B28-brainsci-09-00172"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskowitz</surname><given-names>M.A.</given-names></name></person-group><article-title>Neurogenic inflammation in the pathophysiology and treatment of migraine</article-title><source>Neurology</source><year>1993</year><volume>43</volume><issue>Suppl. S3</issue><fpage>S16</fpage><lpage>S20</lpage><?supplied-pmid 8389008?><pub-id pub-id-type="pmid">8389008</pub-id></element-citation></ref><ref id="B29-brainsci-09-00172"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waeber</surname><given-names>C.</given-names></name><name><surname>Moskowitz</surname><given-names>M.A.</given-names></name></person-group><article-title>Migraine as an inflammatory disorder</article-title><source>Neurology</source><year>2012</year><pub-id pub-id-type="doi">10.1212/WNL.64.10_suppl_2.S9</pub-id></element-citation></ref><ref id="B30-brainsci-09-00172"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vecchia</surname><given-names>D.</given-names></name><name><surname>Pietrobon</surname><given-names>D.</given-names></name></person-group><article-title>Migraine: A disorder of brain excitatory-inhibitory balance?</article-title><source>Trends Neurosci.</source><year>2012</year><volume>35</volume><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2012.04.007</pub-id><pub-id pub-id-type="pmid">22633369</pub-id></element-citation></ref><ref id="B31-brainsci-09-00172"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceruti</surname><given-names>S.</given-names></name><name><surname>Villa</surname><given-names>G.</given-names></name><name><surname>Fumagalli</surname><given-names>M.</given-names></name><name><surname>Colombo</surname><given-names>L.</given-names></name><name><surname>Magni</surname><given-names>G.</given-names></name><name><surname>Zanardelli</surname><given-names>M.</given-names></name><name><surname>Fabbretti</surname><given-names>E.</given-names></name><name><surname>Verderio</surname><given-names>C.</given-names></name><name><surname>van den Maagdenberg</surname><given-names>A.M.J.M.</given-names></name><name><surname>Nistri</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Calcitonin Gene-Related Peptide-Mediated Enhancement of Purinergic Neuron/Glia Communication by the Algogenic Factor Bradykinin in Mouse Trigeminal Ganglia from Wild-Type and R192Q Cav2.1 Knock-In Mice: Implications for Basic Mechanisms of Migraine Pain</article-title><source>J. Neurosci.</source><year>2011</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6440-10.2011</pub-id></element-citation></ref><ref id="B32-brainsci-09-00172"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>M.H.</given-names></name></person-group><article-title>Local inflammation as a mediator of migraine and tension-type headache</article-title><source>Headache</source><year>2004</year><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04143.x</pub-id></element-citation></ref><ref id="B33-brainsci-09-00172"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>B.H.</given-names></name><name><surname>Colman</surname><given-names>I.</given-names></name><name><surname>Edmonds</surname><given-names>M.L.</given-names></name><name><surname>Blitz</surname><given-names>S.</given-names></name><name><surname>Walker</surname><given-names>A.</given-names></name><name><surname>Wiens</surname><given-names>S.</given-names></name></person-group><article-title>Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache</article-title><source>Headache</source><year>2008</year><pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00959.x</pub-id></element-citation></ref><ref id="B34-brainsci-09-00172"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Maagdenberg</surname><given-names>A.M.J.M.</given-names></name><name><surname>Haan</surname><given-names>J.</given-names></name><name><surname>Terwindt</surname><given-names>G.M.</given-names></name><name><surname>Ferrari</surname><given-names>M.D.</given-names></name></person-group><article-title>Migraine: Gene mutations and functional consequences</article-title><source>Curr. Opin. Neurol.</source><year>2007</year><volume>20</volume><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1097/WCO.0b013e3281338d1f</pub-id><pub-id pub-id-type="pmid">17495624</pub-id></element-citation></ref><ref id="B35-brainsci-09-00172"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ophoff</surname><given-names>R.A.</given-names></name><name><surname>Terwindt</surname><given-names>G.M.</given-names></name><name><surname>Vergouwe</surname><given-names>M.N.</given-names></name><name><surname>Van Eijk</surname><given-names>R.</given-names></name><name><surname>Oefner</surname><given-names>P.J.</given-names></name><name><surname>Hoffman</surname><given-names>S.M.G.</given-names></name><name><surname>Lamerdin</surname><given-names>J.E.</given-names></name><name><surname>Mohrenweiser</surname><given-names>H.W.</given-names></name><name><surname>Bulman</surname><given-names>D.E.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4</article-title><source>Cell</source><year>1996</year><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81373-2</pub-id></element-citation></ref><ref id="B36-brainsci-09-00172"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Maagdenberg</surname><given-names>A.M.J.M.</given-names></name><name><surname>Pietrobon</surname><given-names>D.</given-names></name><name><surname>Pizzorusso</surname><given-names>T.</given-names></name><name><surname>Kaja</surname><given-names>S.</given-names></name><name><surname>Broos</surname><given-names>L.A.M.</given-names></name><name><surname>Cesetti</surname><given-names>T.</given-names></name><name><surname>Van De Ven</surname><given-names>R.C.G.</given-names></name><name><surname>Tottene</surname><given-names>A.</given-names></name><name><surname>Van Der Kaa</surname><given-names>J.</given-names></name><name><surname>Plomp</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression</article-title><source>Neuron</source><year>2004</year><pub-id pub-id-type="doi">10.1016/S0896-6273(04)00085-6</pub-id></element-citation></ref><ref id="B37-brainsci-09-00172"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurkat-Rott</surname><given-names>K.</given-names></name><name><surname>Lerche</surname><given-names>H.</given-names></name><name><surname>Weber</surname><given-names>Y.</given-names></name><name><surname>Lehmann-Horn</surname><given-names>F.</given-names></name></person-group><article-title>Hereditary channelopathies in neurology</article-title><source>Adv. Exp. Med. Biol.</source><year>2010</year><volume>686</volume><fpage>305</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">20824453</pub-id></element-citation></ref><ref id="B38-brainsci-09-00172"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P.C.</given-names></name><name><surname>Koehler</surname><given-names>P.J.</given-names></name></person-group><article-title>One hundred years of migraine research: Major clinical and scientific observations from 1910 to 2010</article-title><source>Headache</source><year>2011</year><volume>51</volume><fpage>752</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2011.01892.x</pub-id><pub-id pub-id-type="pmid">21521208</pub-id></element-citation></ref><ref id="B39-brainsci-09-00172"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tottene</surname><given-names>A.</given-names></name><name><surname>Conti</surname><given-names>R.</given-names></name><name><surname>Fabbro</surname><given-names>A.</given-names></name><name><surname>Vecchia</surname><given-names>D.</given-names></name><name><surname>Shapovalova</surname><given-names>M.</given-names></name><name><surname>Santello</surname><given-names>M.</given-names></name><name><surname>van den Maagdenberg</surname><given-names>A.M.J.M.</given-names></name><name><surname>Ferrari</surname><given-names>M.D.</given-names></name><name><surname>Pietrobon</surname><given-names>D.</given-names></name></person-group><article-title>Enhanced Excitatory Transmission at Cortical Synapses as the Basis for Facilitated Spreading Depression in CaV2.1 Knockin Migraine Mice</article-title><source>Neuron</source><year>2009</year><pub-id pub-id-type="doi">10.1016/j.neuron.2009.01.027</pub-id></element-citation></ref><ref id="B40-brainsci-09-00172"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatas</surname><given-names>H.</given-names></name><name><surname>Erdener</surname><given-names>S.E.</given-names></name><name><surname>Gursoy-Ozdemir</surname><given-names>Y.</given-names></name><name><surname>Lule</surname><given-names>S.</given-names></name><name><surname>Eren-Ko&#x000e7;ak</surname><given-names>E.</given-names></name><name><surname>Sen</surname><given-names>Z.D.</given-names></name><name><surname>Dalkara</surname><given-names>T.</given-names></name></person-group><article-title>Spreading depression triggers headache by activating neuronal Panx1 channels</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>1092</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1126/science.1231897</pub-id><pub-id pub-id-type="pmid">23449592</pub-id></element-citation></ref><ref id="B41-brainsci-09-00172"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noseda</surname><given-names>R.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain</article-title><source>Pain</source><year>2013</year><volume>154</volume><issue>Suppl. S1</issue><fpage>S44</fpage><lpage>S53</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.07.021</pub-id><pub-id pub-id-type="pmid">23891892</pub-id></element-citation></ref><ref id="B42-brainsci-09-00172"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Levy</surname><given-names>D.</given-names></name><name><surname>Kainz</surname><given-names>V.</given-names></name><name><surname>Noseda</surname><given-names>R.</given-names></name><name><surname>Jakubowski</surname><given-names>M.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Activation of central trigeminovascular neurons by cortical spreading depression</article-title><source>Ann. Neurol.</source><year>2011</year><pub-id pub-id-type="doi">10.1002/ana.22329</pub-id></element-citation></ref><ref id="B43-brainsci-09-00172"><label>43.</label><element-citation publication-type="gov"><article-title>GEO DataSets</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gds">https://www.ncbi.nlm.nih.gov/gds</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B44-brainsci-09-00172"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eising</surname><given-names>E.</given-names></name><name><surname>Shyti</surname><given-names>R.</given-names></name><name><surname>&#x02019;t Hoen</surname><given-names>P.A.C.</given-names></name><name><surname>Vijfhuizen</surname><given-names>L.S.</given-names></name><name><surname>Huisman</surname><given-names>S.M.H.</given-names></name><name><surname>Broos</surname><given-names>L.A.M.</given-names></name><name><surname>Mahfouz</surname><given-names>A.</given-names></name><name><surname>Reinders</surname><given-names>M.J.T.</given-names></name><name><surname>Ferrari</surname><given-names>M.D.</given-names></name><name><surname>Tolner</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Cortical Spreading Depression Causes Unique Dysregulation of Inflammatory Pathways in a Transgenic Mouse Model of Migraine</article-title><source>Mol. Neurobiol.</source><year>2017</year><pub-id pub-id-type="doi">10.1007/s12035-015-9681-5</pub-id></element-citation></ref><ref id="B45-brainsci-09-00172"><label>45.</label><element-citation publication-type="web"><article-title>STRING</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B46-brainsci-09-00172"><label>46.</label><element-citation publication-type="web"><article-title>Heatmapper</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.heatmapper.ca/">http://www.heatmapper.ca/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B47-brainsci-09-00172"><label>47.</label><element-citation publication-type="web"><article-title>CoExpress software</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.lu/coexpress/">http://www. bioinformatics.lu/coexpress/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B48-brainsci-09-00172"><label>48.</label><element-citation publication-type="gov"><article-title>DAVID version 6.8</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/">http://david.abcc.ncifcrf.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B49-brainsci-09-00172"><label>49.</label><element-citation publication-type="web"><article-title>IBM SPSS Statistics 23</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.spss.it/">https://www.spss.it/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B50-brainsci-09-00172"><label>50.</label><element-citation publication-type="web"><article-title>GraphPad Prism 8.0.2</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-15">(accessed on 15 April 2019)</date-in-citation></element-citation></ref><ref id="B51-brainsci-09-00172"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>R.</given-names></name></person-group><article-title>Understanding migraine: Potential role of neurogenic inflammation</article-title><source>Ann. Indian Acad. Neurol.</source><year>2016</year><pub-id pub-id-type="doi">10.4103/0972-2327.182302</pub-id></element-citation></ref><ref id="B52-brainsci-09-00172"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>R.</given-names></name></person-group><article-title>Neurogenic inflammation and its role in migraine</article-title><source>Semin. Immunopathol.</source><year>2018</year><volume>40</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s00281-018-0676-y</pub-id><pub-id pub-id-type="pmid">29568973</pub-id></element-citation></ref><ref id="B53-brainsci-09-00172"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>M.M.</given-names></name><name><surname>Rapoport</surname><given-names>A.M.</given-names></name></person-group><article-title>Triptans for the management of migraine</article-title><source>Drugs</source><year>2010</year><volume>70</volume><fpage>1505</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.2165/11537990-000000000-00000</pub-id><pub-id pub-id-type="pmid">20687618</pub-id></element-citation></ref><ref id="B54-brainsci-09-00172"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>A.B.</given-names></name><name><surname>Bachi</surname><given-names>A.L.L.</given-names></name><name><surname>Ribeiro</surname><given-names>R.T.</given-names></name><name><surname>Mello</surname><given-names>M.T.</given-names></name><name><surname>Tufik</surname><given-names>S.</given-names></name><name><surname>Peres</surname><given-names>M.F.P.</given-names></name></person-group><article-title>Unbalanced plasma TNF-&#x003b1; and IL-12/IL-10 profile in women with migraine is associated with psychological and physiological outcomes</article-title><source>J. Neuroimmunol.</source><year>2017</year><volume>313</volume><fpage>138</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2017.09.008</pub-id><pub-id pub-id-type="pmid">28950996</pub-id></element-citation></ref><ref id="B55-brainsci-09-00172"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>C.</given-names></name><name><surname>Tozzi</surname><given-names>A.</given-names></name><name><surname>Rainero</surname><given-names>I.</given-names></name><name><surname>Cupini</surname><given-names>L.M.</given-names></name><name><surname>Calabresi</surname><given-names>P.</given-names></name><name><surname>Ayata</surname><given-names>C.</given-names></name><name><surname>Sarchielli</surname><given-names>P.</given-names></name></person-group><article-title>Cortical spreading depression as a target for anti-migraine agents</article-title><source>J. Headache Pain</source><year>2013</year><pub-id pub-id-type="doi">10.1186/1129-2377-14-62</pub-id></element-citation></ref><ref id="B56-brainsci-09-00172"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>C.S.</given-names></name><name><surname>Hakim</surname><given-names>A.M.</given-names></name></person-group><article-title>Cortical Spreading Depression Modifies Components of the Inflammatory Cascade</article-title><source>Mol. Neurobiol.</source><year>2005</year><pub-id pub-id-type="doi">10.1385/MN:32:1:051</pub-id></element-citation></ref><ref id="B57-brainsci-09-00172"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhuri</surname><given-names>R.</given-names></name><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Yong</surname><given-names>C.</given-names></name><name><surname>Bowyer</surname><given-names>S.</given-names></name><name><surname>Klein</surname><given-names>R.M.</given-names></name><name><surname>Welch</surname><given-names>K.M.A.</given-names></name><name><surname>Berman</surname><given-names>N.E.J.</given-names></name></person-group><article-title>Cortical spreading depression and gene regulation: Relevance to migraine</article-title><source>Ann. Neurol.</source><year>2002</year><pub-id pub-id-type="doi">10.1002/ana.10158</pub-id></element-citation></ref><ref id="B58-brainsci-09-00172"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbach</surname><given-names>A.</given-names></name><name><surname>Bruehl</surname><given-names>C.</given-names></name><name><surname>Witte</surname><given-names>O.W.</given-names></name></person-group><article-title>Microarray-based long-term detection of genes differentially expressed after cortical spreading depression</article-title><source>Eur. J. Neurosci.</source><year>2006</year><pub-id pub-id-type="doi">10.1111/j.1460-9568.2006.04862.x</pub-id></element-citation></ref><ref id="B59-brainsci-09-00172"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Cavalli</surname><given-names>E.</given-names></name><name><surname>Bramanti</surname><given-names>A.</given-names></name><name><surname>Petralia</surname><given-names>M.C.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Al-Abed</surname><given-names>Y.</given-names></name><name><surname>Bramati</surname><given-names>P.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name></person-group><article-title>Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences</article-title><source>J. Neuroimmunol.</source><year>2018</year><fpage>322</fpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2018.06.009</pub-id></element-citation></ref><ref id="B60-brainsci-09-00172"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Di Marco</surname><given-names>R.</given-names></name><name><surname>Spinasanta</surname><given-names>F.</given-names></name><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Petralia</surname><given-names>M.C.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name></person-group><article-title>Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment</article-title><source>Mol. Med. Rep.</source><year>2019</year><volume>20</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.3892/mmr.2019.10283</pub-id><pub-id pub-id-type="pmid">31180553</pub-id></element-citation></ref><ref id="B61-brainsci-09-00172"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Cavalli</surname><given-names>E.</given-names></name><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Petralia</surname><given-names>M.C.</given-names></name><name><surname>McCubrey</surname><given-names>J.A.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name></person-group><article-title>Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>8263</fpage><lpage>8277</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23862</pub-id><pub-id pub-id-type="pmid">29492193</pub-id></element-citation></ref><ref id="B62-brainsci-09-00172"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Muthumani</surname><given-names>K.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Magro</surname><given-names>G.</given-names></name><name><surname>Meroni</surname><given-names>P.L.</given-names></name><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Sardesai</surname><given-names>N.Y.</given-names></name><name><surname>Weiner</surname><given-names>D.B.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name></person-group><article-title>VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus</article-title><source>Immunology</source><year>2014</year><volume>142</volume><pub-id pub-id-type="doi">10.1111/imm.12267</pub-id></element-citation></ref><ref id="B63-brainsci-09-00172"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presti</surname><given-names>M.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Petralia</surname><given-names>M.C.</given-names></name><name><surname>Bramanti</surname><given-names>A.</given-names></name><name><surname>Colletti</surname><given-names>G.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Fagone</surname><given-names>P.</given-names></name></person-group><article-title>Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma</article-title><source>Oncol. Lett.</source><year>2018</year><volume>16</volume><fpage>2881</fpage><lpage>2886</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8990</pub-id><pub-id pub-id-type="pmid">30127875</pub-id></element-citation></ref><ref id="B64-brainsci-09-00172"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Caltabiano</surname><given-names>R.</given-names></name><name><surname>Russo</surname><given-names>A.</given-names></name><name><surname>Lupo</surname><given-names>G.</given-names></name><name><surname>Anfuso</surname><given-names>C.D.</given-names></name><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Longo</surname><given-names>A.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>De Pasquale</surname><given-names>R.</given-names></name><name><surname>Libra</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Identification of novel chemotherapeutic strategies for metastatic uveal melanoma</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>44564</fpage><pub-id pub-id-type="doi">10.1038/srep44564</pub-id><pub-id pub-id-type="pmid">28303962</pub-id></element-citation></ref><ref id="B65-brainsci-09-00172"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Russo</surname><given-names>A.</given-names></name><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Longo</surname><given-names>A.</given-names></name><name><surname>Bonfiglio</surname><given-names>V.</given-names></name><name><surname>Fallico</surname><given-names>M.</given-names></name><name><surname>Caltabiano</surname><given-names>R.</given-names></name><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Differential modulation and prognostic values of immune-escape genes in uveal melanoma</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0210276</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0210276</pub-id><pub-id pub-id-type="pmid">30653520</pub-id></element-citation></ref><ref id="B66-brainsci-09-00172"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Di Marco</surname><given-names>R.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Petralia</surname><given-names>M.C.</given-names></name><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name></person-group><article-title>Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>17951</fpage><lpage>17970</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24885</pub-id><pub-id pub-id-type="pmid">29707160</pub-id></element-citation></ref><ref id="B67-brainsci-09-00172"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Pesce</surname><given-names>A.</given-names></name><name><surname>Pesce</surname><given-names>A.</given-names></name><name><surname>Caltabiano</surname><given-names>R.</given-names></name><name><surname>Giorlandino</surname><given-names>A.</given-names></name><name><surname>Portale</surname><given-names>T.R.</given-names></name><name><surname>Cavalli</surname><given-names>E.</given-names></name><name><surname>Lombardo</surname><given-names>G.A.G.</given-names></name><etal/></person-group><article-title>Identification of novel targets for the diagnosis and treatment of liver fibrosis</article-title><source>Int. J. Mol. Med.</source><year>2015</year><volume>36</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2015.2264</pub-id><pub-id pub-id-type="pmid">26135677</pub-id></element-citation></ref><ref id="B68-brainsci-09-00172"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>K.</given-names></name><name><surname>Cavalli</surname><given-names>E.</given-names></name><name><surname>Mammana</surname><given-names>S.</given-names></name><name><surname>Basile</surname><given-names>M.S.</given-names></name><name><surname>Caltabiano</surname><given-names>R.</given-names></name><name><surname>Pesce</surname><given-names>A.</given-names></name><name><surname>Puleo</surname><given-names>S.</given-names></name><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Magro</surname><given-names>G.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Involvement of the Nrf2/HO-1/CO axis and therapeutic intervention with the CO-releasing molecule CORM-A1, in a murine model of autoimmune hepatitis</article-title><source>J. Cell. Physiol.</source><year>2018</year><volume>233</volume><fpage>4156</fpage><lpage>4165</lpage><pub-id pub-id-type="doi">10.1002/jcp.26223</pub-id><pub-id pub-id-type="pmid">29034470</pub-id></element-citation></ref><ref id="B69-brainsci-09-00172"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagone</surname><given-names>P.</given-names></name><name><surname>Nunnari</surname><given-names>G.</given-names></name><name><surname>Lazzara</surname><given-names>F.</given-names></name><name><surname>Longo</surname><given-names>A.</given-names></name><name><surname>Cambria</surname><given-names>D.</given-names></name><name><surname>Distefano</surname><given-names>G.</given-names></name><name><surname>Palumbo</surname><given-names>M.</given-names></name><name><surname>Nicoletti</surname><given-names>F.</given-names></name><name><surname>Malaguarnera</surname><given-names>L.</given-names></name><name><surname>Di Rosa</surname><given-names>M.</given-names></name></person-group><article-title>Induction of OAS gene family in HIV monocyte infected patients with high and low viral load</article-title><source>Antivir. Res.</source><year>2016</year><volume>131</volume><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.04.009</pub-id></element-citation></ref><ref id="B70-brainsci-09-00172"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arend</surname><given-names>W.P.</given-names></name><name><surname>Gabay</surname><given-names>C.</given-names></name></person-group><article-title>Physiologic role of interleukin-1 receptor antagonist</article-title><source>Arthritis Res.</source><year>2000</year><volume>2</volume><fpage>245</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1186/ar94</pub-id><pub-id pub-id-type="pmid">11094434</pub-id></element-citation></ref><ref id="B71-brainsci-09-00172"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>B.D.</given-names></name><name><surname>Buchman</surname><given-names>T.G.</given-names></name></person-group><article-title>Interleukin-1 receptor antagonist as therapy for inflammatory disorders</article-title><source>Expert Opin. Biol.</source><year>2005</year><pub-id pub-id-type="doi">10.1517/14712598.1.2.301</pub-id></element-citation></ref><ref id="B72-brainsci-09-00172"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f8;</surname><given-names>S.H.</given-names></name><name><surname>Davidsen</surname><given-names>E.M.</given-names></name><name><surname>Gulbrandsen</surname><given-names>P.</given-names></name><name><surname>Dietrichs</surname><given-names>E.</given-names></name><name><surname>Bovim</surname><given-names>G.</given-names></name><name><surname>Stovner</surname><given-names>L.J.</given-names></name><name><surname>White</surname><given-names>L.R.</given-names></name></person-group><article-title>Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache</article-title><source>Cephalalgia</source><year>2009</year><pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01727.x</pub-id></element-citation></ref><ref id="B73-brainsci-09-00172"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilg</surname><given-names>H.</given-names></name><name><surname>Trehu</surname><given-names>E.</given-names></name><name><surname>Atkins</surname><given-names>M.B.</given-names></name><name><surname>Dinarello</surname><given-names>C.A.</given-names></name><name><surname>Mier</surname><given-names>J.W.</given-names></name></person-group><article-title>Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55</article-title><source>Blood</source><year>1994</year><volume>83</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">8274730</pub-id></element-citation></ref><ref id="B74-brainsci-09-00172"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilg</surname><given-names>H.</given-names></name><name><surname>Mier</surname><given-names>J.W.</given-names></name><name><surname>Vogel</surname><given-names>W.</given-names></name><name><surname>Aulitzky</surname><given-names>W.E.</given-names></name><name><surname>Wiedermann</surname><given-names>C.J.</given-names></name><name><surname>Vannier</surname><given-names>E.</given-names></name><name><surname>Huber</surname><given-names>C.</given-names></name><name><surname>Dinarello</surname><given-names>C.A.</given-names></name></person-group><article-title>Induction of circulating IL-1 receptor antagonist by IFN treatment</article-title><source>J. Immunol.</source><year>1993</year><volume>150</volume><fpage>4678</fpage><lpage>4692</lpage></element-citation></ref><ref id="B75-brainsci-09-00172"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arslan</surname><given-names>H.H.</given-names></name><name><surname>Tokg&#x000f6;z</surname><given-names>E.</given-names></name><name><surname>Yildizo&#x00287;lu</surname><given-names>&#x000dc;.</given-names></name><name><surname>Durmaz</surname><given-names>A.</given-names></name><name><surname>Bek</surname><given-names>S.</given-names></name><name><surname>Gerek</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of the changes in the nasal cavity during the migraine attack</article-title><source>J. Craniofac. Surg.</source><year>2014</year><pub-id pub-id-type="doi">10.1097/SCS.0b013e31827c80b1</pub-id></element-citation></ref><ref id="B76-brainsci-09-00172"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aukerman</surname><given-names>G.</given-names></name><name><surname>Knutson</surname><given-names>D.</given-names></name><name><surname>Miser</surname><given-names>W.F.</given-names></name></person-group><article-title>Management of the acute migraine headache</article-title><source>Am. Fam. Physician</source><year>2002</year><volume>66</volume><fpage>2123</fpage><lpage>2130</lpage><pub-id pub-id-type="pmid">12484694</pub-id></element-citation></ref><ref id="B77-brainsci-09-00172"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>Y.C.</given-names></name><name><surname>Lin</surname><given-names>K.C.</given-names></name><name><surname>Wang</surname><given-names>S.J.</given-names></name><name><surname>Wang</surname><given-names>P.J.</given-names></name><name><surname>Wang</surname><given-names>Y.F.</given-names></name><name><surname>Lee</surname><given-names>L.H.</given-names></name><name><surname>Wu</surname><given-names>Z.A.</given-names></name><name><surname>Shih</surname><given-names>C.S.</given-names></name><name><surname>Chen</surname><given-names>Y.Y.</given-names></name><name><surname>Chen</surname><given-names>W.H.</given-names></name><etal/></person-group><article-title>Medical treatment guidelines for acute migraine attacks</article-title><source>Acta Neurol. Taiwan.</source><year>2017</year><volume>26</volume><fpage>78</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">29250761</pub-id></element-citation></ref><ref id="B78-brainsci-09-00172"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raffaelli</surname><given-names>B.</given-names></name><name><surname>Mussetto</surname><given-names>V.</given-names></name><name><surname>Israel</surname><given-names>H.</given-names></name><name><surname>Neeb</surname><given-names>L.</given-names></name><name><surname>Reuter</surname><given-names>U.</given-names></name></person-group><article-title>Erenumab and galcanezumab in chronic migraine prevention: Effects after treatment termination</article-title><source>J. Headache Pain</source><year>2019</year><volume>20</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/s10194-019-1018-8</pub-id><pub-id pub-id-type="pmid">31159727</pub-id></element-citation></ref><ref id="B79-brainsci-09-00172"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Stauffer</surname><given-names>V.L.</given-names></name><name><surname>Day</surname><given-names>K.A.</given-names></name><name><surname>Lipsius</surname><given-names>S.</given-names></name><name><surname>Wilson</surname><given-names>M.-C.</given-names></name></person-group><article-title>Galcanezumab in episodic migraine: Subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 &#x00026; EVOLVE-2)</article-title><source>J. Headache Pain</source><year>2019</year><volume>20</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s10194-019-1024-x</pub-id><pub-id pub-id-type="pmid">31253091</pub-id></element-citation></ref><ref id="B80-brainsci-09-00172"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Silberstein</surname><given-names>S.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Biondi</surname><given-names>D.</given-names></name><name><surname>Hirman</surname><given-names>J.</given-names></name><name><surname>Cady</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name></person-group><article-title>Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial</article-title><source>Cephalalgia</source><year>2019</year><pub-id pub-id-type="doi">10.1177/0333102419858355</pub-id></element-citation></ref><ref id="B81-brainsci-09-00172"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Cohen</surname><given-names>J.M.</given-names></name><name><surname>Yeung</surname><given-names>P.P.</given-names></name></person-group><article-title>Fremanezumab for the preventive treatment of migraine</article-title><source>Expert Opin. Biol.</source><year>2019</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/14712598.2019.1627323</pub-id></element-citation></ref><ref id="B82-brainsci-09-00172"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neven</surname><given-names>B.</given-names></name><name><surname>Marvillet</surname><given-names>I.</given-names></name><name><surname>Terrada</surname><given-names>C.</given-names></name><name><surname>Ferster</surname><given-names>A.</given-names></name><name><surname>Boddaert</surname><given-names>N.</given-names></name><name><surname>Couloignier</surname><given-names>V.</given-names></name><name><surname>Pinto</surname><given-names>G.</given-names></name><name><surname>Pagnier</surname><given-names>A.</given-names></name><name><surname>Bodemer</surname><given-names>C.</given-names></name><name><surname>Tardieu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome</article-title><source>Arthritis Rheum.</source><year>2010</year><pub-id pub-id-type="doi">10.1002/art.25057</pub-id></element-citation></ref><ref id="B83-brainsci-09-00172"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landmann</surname><given-names>E.C.</given-names></name><name><surname>Walker</surname><given-names>U.A.</given-names></name></person-group><article-title>Pharmacological treatment options for cryopyrin-associated periodic syndromes</article-title><source>Expert Rev. Clin. Pharm.</source><year>2017</year><volume>10</volume><fpage>855</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1080/17512433.2017.1338946</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="brainsci-09-00172-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><italic>IL-1RN</italic> expression in a model of migraine. The expression of <italic>IL-1RN</italic> was investigated in mice bearing the R192Q mutation and wild&#x02013;type (WT) mice at baseline and following CSD, as determined in the GSE67933 dataset. Data are presented as trimmed mean of M-values (TMM) normalized expression.</p></caption><graphic xlink:href="brainsci-09-00172-g001"/></fig><fig id="brainsci-09-00172-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><italic>IL-1RN</italic> functionally-related genes. (<bold>A</bold>) Gene network of the <italic>IL-1RN</italic> functionally related genes. The edges connecting the nodes represent the interactions between genes, in terms of co-expression (black), text mining (light green), protein homology (cyan), association in curated database (light blue), and high-throughput experiments (purple). Empty nodes represent proteins of uncharacterized 3D structure, while filled nodes represent proteins with known or predicted tertiary structure. (<bold>B</bold>) Expression heatmap for the top correlated genes to <italic>IL-1RN</italic>, as determined in the GSE67933 dataset. Average linkage was used as clustering method and Euclidean distance as distance measurement. Tree branches represent the distance between genes.</p></caption><graphic xlink:href="brainsci-09-00172-g002"/></fig><fig id="brainsci-09-00172-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Gene ontology analysis for the genes statistically correlated to <italic>IL-1RN</italic> in the model of cortical spreading depression (CSD)-induced migraine. (<bold>A</bold>) Most enriched biological processes; (<bold>B</bold>) Most enriched molecular functions. FDR: False Discovery Rate</p></caption><graphic xlink:href="brainsci-09-00172-g003"/></fig><table-wrap id="brainsci-09-00172-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">brainsci-09-00172-t001_Table 1</object-id><label>Table 1</label><caption><p>Top 20 genes statistically correlated to <italic>IL-1RN</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Stable ID</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pearson r</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95% Confidence Interval</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>R</italic> Squared</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cdhr5</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000025497</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9996</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9991 to 0.9998</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9992</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gm8251</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000091844</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9996</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9991 to 0.9998</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9993</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Scarna3b</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000088158</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9993</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9983 to 0.9997</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9986</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nr0b1</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000025056</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9991</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9980 to 0.9996</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9983</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lrrc15</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000052316</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9987</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9968 to 0.9994</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9973</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ifi204</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000073489</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9982</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9959 to 0.9993</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9965</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cd200r3</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000036172</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9981</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9955 to 0.9992</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9962</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gm13389</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000087079</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9977</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9947 to 0.9990</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9955</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hpx</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000030895</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9976</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9944 to 0.9990</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9953</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gm15941</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000086992</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9974</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9940 to 0.9989</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9949</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zc3h12d</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000039981</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9973</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9938 to 0.9989</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9947</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gm49339</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000062593</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9973</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9936 to 0.9988</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9945</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Klre1</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000050241</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9971</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9933 to 0.9988</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9943</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Klk9</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000047884</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9966</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9921 to 0.9986</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9933</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gm22486</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000080465</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9966</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9921 to 0.9986</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9933</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Abo</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000015787</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9965</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9919 to 0.9985</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9931</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cnga3</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000026114</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9965</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9917 to 0.9985</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9929</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ccl4</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000018930</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9960</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9906 to 0.9983</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9920</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Snord66</td><td align="center" valign="middle" rowspan="1" colspan="1">ENSMUSG00000077239</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9958</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9901 to 0.9982</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9916</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gm13429</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ENSMUSG00000085141</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9957</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9898 to 0.9982</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9913</td></tr></tbody></table></table-wrap></floats-group></article>